(Date:5/15/2008)... newly cleared device to identify the, lipid core...ociated with complications of co...swire/ -- InfraReDx, Inc. today,announced that phy...have,successfully used its LipiScan(TM) Coronary I...theterization. This is the first patient in the,wo...
(Date:5/15/2008)...Newswire/ -- Tigris Pharmaceuticals,Inc. announce...d,Development Agreement (CRADA) with the National ...and preclinical development of AFP-464, an,aminofl... converted to,metabolites which bind covalently to... This is part of a four-year CRADA encompassing mu...
(Date:5/15/2008)...CEA Trial data reports in third quarter .../- VIA Pharmaceuticals,Inc...d on the development of,compounds for the treatmen...it has completed patient enrollment in its acute c... of three Phase 2 trials investigating VIA-2291,t...
(Date:5/14/2008)...ewswire-FirstCall/ -- Progen,Pharmaceuticals Limit...e,Company has resumed patient enrolment in the pha...d polyamine analogue, PG-11047 (formerly CGC-11047...commenced development of PG-11047 - the lead clini...following its acquisition of,Cellgate, Inc earlier...
Breaking Medicine Technology:First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 2First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 3First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 4Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047 2New Website Showcases 24 Promising Models That Are Transforming How Health Care Is Delivered 17049 1New Website Showcases 24 Promising Models That Are Transforming How Health Care Is Delivered 17049 2New Website Showcases 24 Promising Models That Are Transforming How Health Care Is Delivered 17049 3New Website Showcases 24 Promising Models That Are Transforming How Health Care Is Delivered 17049 4Susan G Komen for the Cure Advocacy Alliance Suggests Questions for Tonights Presidential Debate 17047 1Susan G Komen for the Cure Advocacy Alliance Suggests Questions for Tonights Presidential Debate 17047 2National Restaurant Association Expresses Disappointment About Court Ruling on Menu Labeling in New York City 17045 1National Restaurant Association Expresses Disappointment About Court Ruling on Menu Labeling in New York City 17045 2Advanced Life Sciences Regains Compliance With Nasdaq Listing Requirements 4661 1Advanced Life Sciences Regains Compliance With Nasdaq Listing Requirements 4661 2...007 - Roche today announced,results of a small stu...d treatment with Peg-Intron(R) (peginterferon alfa...e first 12 weeks, were,able to complete 12 weeks o...) and ribavirin. Furthermore, 92 percent of,these ...urse of,treatment with PEGASYS. The data, which we...
...irstCall/ -- Bristol-Myers,Squibb Company (NYSE: B...hich showed that treatment with Baraclude (entecav... adefovir at 48 weeks,-- a result that was also se...ta from an open-label, randomized viral kinetics s...ntigen (HBeAg),positive patients were presented at...
Other Medicine Technology:Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 2Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 3Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 4Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 5Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 6Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 2Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 3Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 4Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 5Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 6(Date:5/16/2008)...e of Oral and Overall Health, HARRISBURG, Pa., Ma...d,Concordia Dental is celebrating National Smile M...and the British Dental Health Foundation to,promot... Beginning May 18,this year,s event is launching ... the largest independent international dental heal...
(Date:5/16/2008)...ociety of Clinical Oncology meeting in Chicago (Ab...out 25 percent of patients with colon cancer and i...ctal cancers will be staged. , This new study,...tion-based statistic registries from 1992 to 2004,...comes of patients with positive nodes (Stage III) ...
(Date:5/16/2008)...fit from calcitriol, an oral form , , FR...vitamin D may cut the risk of death for people wit...ut one quarter, a new study suggests. , During...se being treated with calcitriol, an oral form of ...th lowered by 26 percent when compared with those ...
(Date:5/16/2008)...g of the uterus (submucosal) are more likely to mo...embolization (UAE) but usually dont cause major co...udy included 49 patients with 140 fibroids who und...e study found that 39 of these were submucosal. Of...er UAE, said Sachit Verma, MD, lead author of the ...
Breaking Medicine News(10 mins):Health News:United Concordia Dental Celebrates National Smile Month 2Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 20.6mm Tip x10mm Shaft, Gently Curved From Tip to Bend, 90 Degree Hook at Tip; overall length 120mm; in Titianium.
The SURPASS Perfusion Catheter is indicated for balloon dilatation of the stenotic portion of a coronary artery or bypass graft stenosis for the purpose of improving myocardial perfusion. The SURPASS
Angled 45 Degrees to Right, 9.5mm blade, gently curved .5x .25mm blunt tips; Lower blade is 0.5mm longer; 14mm from mid screw to tip; (Available in left and right;) overall length 120mm; Stainless
9mm Curved Blades with Sharp Pointed Tips; overall length 90mm; Stainless Steel.
Medicine Products: